Current Computer-Aided Drug Design

Scope & Guideline

Empowering Researchers with Insights in Computer-Aided Drug Development

Introduction

Welcome to the Current Computer-Aided Drug Design information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Current Computer-Aided Drug Design, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1573-4099
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCURR COMPUT-AID DRUG / Curr. Comput.-Aided Drug Des.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

The journal 'Current Computer-Aided Drug Design' focuses on the advancement of computational methods and technologies in drug design and discovery. It encompasses a wide range of methodologies aimed at predicting, modeling, and validating potential drug candidates, thus contributing significantly to the field of pharmacology and medicinal chemistry.
  1. Computational Drug Design and Discovery:
    The journal emphasizes methodologies for computational drug design, including molecular docking, QSAR modeling, and molecular dynamics simulations, to identify and optimize potential drug candidates.
  2. Network Pharmacology:
    A significant focus is placed on network pharmacology, which integrates systems biology with pharmacological data to understand drug mechanisms and interactions within biological networks.
  3. In Silico Evaluation:
    The use of in silico approaches for evaluating the pharmacokinetic and toxicological profiles of drug candidates is a core area, ensuring that new compounds are not only effective but also safe for use.
  4. Integration of Traditional and Modern Approaches:
    The journal publishes studies that explore the integration of traditional medicine practices with modern computational techniques, particularly in the context of natural product drug discovery.
  5. AI and Machine Learning in Drug Design:
    There is a growing emphasis on the application of artificial intelligence and machine learning methods to predict drug-target interactions, optimize drug design processes, and analyze large datasets.
The journal 'Current Computer-Aided Drug Design' is witnessing several emerging trends that reflect the current landscape of drug discovery and design. These trends highlight the innovative applications of computational techniques in addressing contemporary challenges in pharmacology.
  1. Artificial Intelligence and Machine Learning:
    The application of AI and machine learning techniques for predicting drug interactions and optimizing drug design is rapidly gaining traction, reflecting a broader trend in the pharmaceutical industry towards data-driven decision making.
  2. Multi-target Drug Design:
    Emerging research is increasingly focusing on multi-target drug design strategies, which consider the complex interactions within biological systems, thus enhancing the effectiveness of therapeutic agents.
  3. Integration of Big Data and Bioinformatics:
    There is a growing trend towards leveraging big data and bioinformatics tools to analyze vast datasets for drug discovery, enabling more informed predictions and insights into drug efficacy and safety.
  4. Virtual Screening Techniques:
    Advanced virtual screening methodologies, including hybrid approaches that combine multiple computational techniques, are becoming prevalent as researchers seek to streamline the drug discovery process.
  5. Mechanistic Studies Using Network Pharmacology:
    The use of network pharmacology to elucidate the mechanisms of action of drugs and their interactions within biological systems is on the rise, emphasizing a systems biology approach to drug discovery.

Declining or Waning

As the field of computer-aided drug design evolves, certain themes appear to be waning in prominence. The following areas have been observed to decline in recent publications, indicating a shift in focus toward more contemporary methodologies and applications.
  1. Traditional Medicinal Approaches:
    While traditional medicinal approaches have been significant in the past, there has been a noticeable decline in studies solely focused on herbal or traditional remedies without the integration of computational methods.
  2. Basic Pharmacological Studies:
    Basic pharmacological studies, which do not employ advanced computational techniques, are becoming less frequent as the journal shifts towards more technologically-driven research.
  3. Single-target Drug Design:
    Research that focuses on single-target drug design is decreasing as there is a growing recognition of the importance of polypharmacology and multi-target approaches in drug development.
  4. In vitro Studies without Computational Validation:
    There is a decline in the publication of in vitro studies that do not include computational validation or modeling, reflecting a preference for studies that integrate both experimental and computational methods.

Similar Journals

Records of Natural Products

Illuminating the Path to Sustainable Pharmaceutical Solutions
Publisher: ACG PUBLICATIONSISSN: 1307-6167Frequency: 6 issues/year

Records of Natural Products is a distinguished journal focused on the dynamic fields of Drug Discovery, Organic Chemistry, Pharmacology, and Plant Science. Published by ACG PUBLICATIONS in Turkey, this journal serves as a vital platform for disseminating innovative research findings and advancements in natural product studies. With its convergence spanning from 2009 to 2024, Records of Natural Products holds a commendable position in the academic realm, featuring a 2023 Q3 ranking in Drug Discovery and Organic Chemistry, alongside a notable Q2 ranking in Plant Science. Despite its current lack of open access, the journal is committed to providing quality content that enriches the understanding of natural products and their potential applications. Researchers and professionals alike can benefit from the journal's insights, which not only contribute to scientific knowledge but also facilitate advancements in pharmaceuticals and sustainable practices. By exploring the rich tapestry of natural product research, this journal underscores its importance as a leading resource for professionals dedicated to enhancing the efficacy and application of natural compounds.

COMPUTATIONAL BIOLOGY AND CHEMISTRY

Pioneering Solutions for Tomorrow’s Biological Challenges with Computational Techniques
Publisher: ELSEVIER SCI LTDISSN: 1476-9271Frequency: 6 issues/year

COMPUTATIONAL BIOLOGY AND CHEMISTRY is a distinguished academic journal published by Elsevier Science Ltd, focusing on the dynamic intersection of computational biology, biochemistry, and chemistry. With an ISSN of 1476-9271 and an E-ISSN of 1476-928X, this journal is committed to disseminating high-quality research that employs computational techniques to solve complex biological and chemical problems. As of 2023, the journal holds a substantial impact factor reflecting its significance and rigorous peer-review process, categorized in the Q2 quartile for both Computational Mathematics and Organic Chemistry, alongside Q3 classifications in Biochemistry and Structural Biology. With a continuous publication history spanning from 2003 to 2024, it serves as a critical resource for researchers, professionals, and students alike. The journal offers various open access options, ensuring that vital research findings are accessible to a global audience, further enhancing collaboration across disciplines. Engage with cutting-edge studies and contribute to the evolving landscape of computational methodologies in the life sciences through this esteemed publication.

BIOORGANIC & MEDICINAL CHEMISTRY

Pioneering Research in Bioorganic Science
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0968-0896Frequency: 24 issues/year

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

MEDICINAL RESEARCH REVIEWS

Exploring Breakthroughs in Drug Discovery and Pharmacology
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

MOLECULAR DIVERSITY

Pioneering Insights into Molecular Complexity
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

Molecular Informatics

Unlocking Insights Through Molecular Modeling
Publisher: WILEY-V C H VERLAG GMBHISSN: 1868-1743Frequency: 12 issues/year

Molecular Informatics is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to advancing the fields of computational analysis and molecular modeling. As a key resource in the realms of Computer Science Applications, Drug Discovery, Molecular Medicine, Organic Chemistry, and Structural Biology, this journal is recognized for its significant contributions and is ranked in the Q2 and Q3 categories across multiple disciplines, positioning it among the leading journals for researchers and academics. With an impressive track record since its inception in 2010 and converging its contributions until 2024, Molecular Informatics aims to bridge the gap between computational techniques and biological applications, promoting interdisciplinary collaboration and innovation. Accessible to a global audience, the journal reflects a commitment to advancing science through open access options, making cutting-edge research available to students, professionals, and decision-makers alike. This journal serves as an indispensable platform for disseminating high-quality research and fostering the development of new theoretical and practical frameworks in molecular informatics.

CURRENT PHARMACEUTICAL DESIGN

Transforming Research into Revolutionary Drug Solutions
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Exploring the Frontiers of Molecular Visualization
Publisher: ELSEVIER SCIENCE INCISSN: 1093-3263Frequency: 6 issues/year

JOURNAL OF MOLECULAR GRAPHICS & MODELLING, published by Elsevier Science Inc, is a leading peer-reviewed journal dedicated to the fields of molecular graphics and modeling. With an ISSN of 1093-3263 and an E-ISSN of 1873-4243, this journal has established its relevance since its inception in 1997, and continues to thrive as it extends its scope into 2024. Acknowledged for its impact in the academic community, it holds a Q2 ranking in both Computer Graphics and Computer-Aided Design and Materials Chemistry, as well as a Q3 ranking in Physical and Theoretical Chemistry and Spectroscopy, reflecting its significance across multidisciplinary research domains. Notably, the journal ranks in the 73rd percentile for Computer Graphics and maintains competitive standings in Materials Science and Chemistry areas. Although it does not currently offer open access options, the journal is an essential resource for researchers, professionals, and students who are engaged in cutting-edge studies and applications in molecular graphics, computational methods, and material design. By facilitating a deeper understanding of molecular interactions through innovative graphical modeling, the journal contributes significantly to advancements in science and technology.

SAR AND QSAR IN ENVIRONMENTAL RESEARCH

Connecting Molecular Science to Ecological Outcomes.
Publisher: TAYLOR & FRANCIS LTDISSN: 1062-936XFrequency: 12 issues/year

SAR and QSAR in Environmental Research is a leading journal published by Taylor & Francis Ltd, focusing on the integration of Structure-Activity Relationships (SAR) and Quantitative Structure-Activity Relationships (QSAR) within the realm of environmental science. Since its inception in 1993, the journal has been a pivotal platform for disseminating innovative research that bridges the gap between chemistry and environmental sustainability, ranking in the Q3 quartile for Bioengineering, Drug Discovery, and miscellaneous Medicine categories as of 2023. Featuring a compelling collection of peer-reviewed articles, it caters to academic and professional audiences seeking to enhance their understanding of molecular interactions and their implications for environmental health. Although the journal does not currently offer Open Access options, its rigorous editorial standards ensure high-quality, impactful publications that are crucial for advancing methodologies in pharmacology, toxicology, and bioengineering. With an ISSN of 1062-936X and an E-ISSN of 1029-046X, SAR and QSAR in Environmental Research continues to serve as an essential resource for researchers, academics, and practitioners dedicated to innovative approaches in environmental research.

Current Research in Structural Biology

Elevating Structural Biology Through Open Access Innovation
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

Current Research in Structural Biology, published by Elsevier, is a pioneering Open Access journal that has rapidly gained prominence since its inception in 2019. With a focus on advancing the understanding of molecular and structural biology, this journal provides a platform for researchers and professionals to publish groundbreaking findings that contribute to the field's ongoing development. With a commendable Q2 ranking in both Molecular Biology and Structural Biology categories for 2023, it serves as a vital resource for the community, ensuring accessibility to high-quality research. The journal is indexed in Scopus, showcasing its significant impact and relevance, particularly with a ranking of #26/49 in the Structural Biology discipline. Located in the heart of the Netherlands, Current Research in Structural Biology not only fosters academic discourse but also encourages collaborative research efforts in addressing critical biological questions. Whether you are a researcher, student, or industry professional, this journal is essential for staying abreast of the latest advancements and trends in structural biology.